Early Patient Access Treatment Use Protocol CA204-220

Summary

The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at Japanese sites where licensed physicians determine clinical need.

Timeline

Start

—

Primary completion

—

Completion

—

Drugs

Indications